Telithromycin for the treatment of acute bacterial maxillary sinusitis: a review of a new antibacterial agent.

Abstract

OBJECTIVE:

Telithromycin, the first approved ketolide antibiotic, was developed to treat community-acquired respiratory tract infections, including acute bacterial maxillary sinusitis (ABMS). A previously published study showed that a 5-day course of 800 mg telithromycin once daily is as effective as a 10-day course in the treatment of ABMS.

MATERIALS AND METHODS:

Data were pooled from two controlled, multinational, prospective, randomized, double-blinded ABMS trials comparing 5-day telithromycin (800 mg once daily) with 10-day amoxicillin-clavulanate (500/125 mg 3 times daily) and cefuroxime axetil (250 mg twice daily). Clinical cure and bacteriologic eradication rates were compared by means of descriptive statistics.

RESULTS:

The clinical cure rate for telithromycin was 80.9% versus 77.4% for comparators; bacteriologic eradication rate for telithromycin was 84.9% versus 81.7% for comparators. Most adverse events were mild to moderate in intensity and, most commonly, gastrointestinal in nature.

CONCLUSIONS:

These results support the conclusion that 5 days of treatment with telithromycin is as safe and effective in patients with ABMS as a 10-day course of treatment with amoxicillin-clavulanate or cefuroxime axetil.

• Authors: Guy Tellier, Stephen A Brunton, Roomi Nusrat
• Journal: Southern medical journal (South Med J) Vol. 98 Issue 9 Pg. 863-8 (Sep 2005) ISSN: 0038-4348 [Print] United States
• PMID: 16217977 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Ketolides
• Amoxicillin-Potassium Clavulanate Combination
• telithromycin
• Cefuroxime
• cefuroxime axetil

Topics

• Acute Disease
• Adolescent
• Adult
• Aged
• Amoxicillin-Potassium Clavulanate Combination (therapeutic use)
• Anti-Bacterial Agents (therapeutic use)
• Cefuroxime (analogs & derivatives, therapeutic use)
• Double-Blind Method
• Drug Administration Schedule
• Female
• Haemophilus influenzae (isolation & purification)
• Humans
• Ketolides (therapeutic use)
• Male
• Maxillary Sinusitis (drug therapy, microbiology)
• Middle Aged
• Moraxella catarrhalis (isolation & purification)
• Prospective Studies
• Randomized Controlled Trials as Topic
• Staphylococcus aureus (isolation & purification)
• Streptococcus pneumoniae (isolation & purification)